TAS::75 0849::TAS "TOPIC 293, A LIQUID BIOPSY TO ASSESS MUTATION IN LUNG CANCER"

实体组织肿瘤患者治疗效果的改善取决于药物靶向肿瘤生长基因突变的能力。目前，突变分析需要侵入性组织活检，这在临床上是不现实的。另外，提取循环肿瘤细胞（CTC）——由原发肿瘤释放到血液中的癌细胞——用于分子分析，为患者特异性肿瘤和突变的基因分型提供了一种有吸引力的策略。该项目的目标是演示和验证一种将高效微流体捕获与集成DNA扩增相结合的程序，以允许直接检测肺癌模型中的驱动突变。突变分析程序的可重复性和准确性将在加标样品中得到验证。此外，该程序将进行测试，以详细说明用于在加标和临床样品中捕获CTC的表面标记。这样，也将评估程序的灵活性。这将产生一种根本性的使能技术，用于个性化医疗中的预测癌症测试，并应用于许多实体肿瘤模型。

Improvement of treatment outcomes for patients with solid tissue tumors depends on the drug¿s ability to target the genetic mutations responsible for tumor growth. Currently, mutational analysis requires an invasive tissue biopsy, which is clinically impractical to perform repeatedly. Alternatively, extracting Circulating Tumor Cells (CTC) - cancer cells released into the bloodstream by the primary tumor - for molecular analysis offers an attractive strategy for genotyping patient-specific tumors and mutations. The goal of this project is to demonstrate and validate a procedure that marries high efficiency microfluidic capture with integrated DNA amplification to allow direct detection of the driver mutations in a lung cancer model. The reproducibility and accuracy of the mutation profiling procedure will be validated in spiked samples. Furthermore, the procedure will be tested to elaborate the surface markers used to capture CTC in spiked and clinical samples. In this way, the flexibility of the procedure will also be assessed. This will produce a fundamentally enabling technology for predictive cancer tests in personalized medicine with application in many solid tumor models.